C

CRISPR Therapeutics AG
D

CRSP

47.840
USD
-2.62
(-5.19%)
مغلق
حجم التداول
143,703
الربح لكل سهم
-4
العائد الربحي
-
P/E
-11
حجم السوق
4,103,450,836
نظرة عامةالتوصياتالأفكار والتحليلاتالأخبار
أصول ذات صلة
    B
    BLUE
    -2.93000
    (-41.68%)
    4.10000 USD
    C
    CRIS
    -0.03400
    (-1.09%)
    3.07600 USD
    E
    EDIT
    -0.14000
    (-6.80%)
    1.92000 USD
    F
    FATE
    -0.13500
    (-8.74%)
    1.41000 USD
    GILD
    GILD
    -0.140
    (-0.13%)
    109.920 USD
    N
    NTLA
    -0.075
    (-0.61%)
    12.180 USD
    PFE
    PFE
    0.405
    (1.56%)
    26.305 USD
    REGN
    REGN
    4.37
    (0.63%)
    700.66 USD
    S
    SGMO
    -0.04500
    (-4.00%)
    1.08000 USD
    VRTX
    VRTX
    4.10
    (0.85%)
    484.53 USD
    المزيد
الأخبار
المقالات

العنوان: CRISPR Therapeutics AG

القطاع: Healthcare
الصناعة: Biotechnology
Crispr Therapeutics AG is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.